A novel biomechanical analysis of gait changes in the MPTP mouse model of Parkinson's disease

PeerJ

Volumn 2015, Issue 8, 2015, Pages

  Geldenhuys, Werner J ^a   Guseman, Tamara L ^b   Pienaar, Ilse S ^c   Dluzen, Dean E ^b,d   Young, Jesse W ^b  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^b Northeast Ohio Medical University   (United States)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Behavior; Gait; Gender bias; Locomotion; MPTP

Indexed keywords

1, 2, 3, 6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; FEMALE; GAIT DISORDER; GENDER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MOUSE; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; VIDEORECORDING;

ANIMALIA; MUS;

EID: 84940395833     PISSN: None     EISSN: 21678359     Source Type: Journal    
DOI: 10.7717/peerj.1175     Document Type: Article

References (43)

1. Amende I, Kale A, McGue S, Glazier S, Morgan JP, Hampton TG. 2005. Gait dynamics in mouse models of Parkinson's disease and Huntingdon's disease. Journal of Neuroengineering and Rehabilitation 2:20 DOI 10.1186/1743-0003-2-20.
2. Antony PM, Diederich NJ, Balling R. 2011. Parkinson's disease mouse models in translational research. Mammalian Genome 22:401-419 DOI 10.1007/s00335-011-9330-x.
3. Antzoulatos E, Jakowec MW, Petzinger GM, Wood RI. 2010. Sex differences in motor behavior in the MPTP mouse model of Parkinson's disease. Pharmacology, Biochemistry and Behavior 95:466-472 DOI 10.1016/j.pbb.2010.03.009.
4. Aviles-Olmos I, Limousin P, Lees A, Foltynie T. 2013. Parkinson's disease, insulin resistance and novel agents of neuroprotection. Brain 136:374-384 DOI 10.1093/brain/aws009.
5. Batka RJ, Brown TJ, McMillan KP, Meadows RM, Jones KJ, Haulcomb MM. 2014. The need for speed in rodent locomotion analyses. The Anatomical Record part A: Discoveries in Molecular, Cellular, and Evolutionary Biology 297:1839-1864 DOI 10.1002/ar.22955.
6. Bezard E, Przedborski S. 2011. A tale on animal models of Parkinson's disease. Movement Disorders 26:993-1002 DOI 10.1002/mds.23696.
7. Blandini F, Armentero MT. 2012. Animal models of Parkinson's disease. FEBS Journal 279:1156-1166 DOI 10.1111/j.1742-4658.2012.08491.x.
8. Bove J, Perier C. 2012. Neurotoxin-based models of Parkinson's disease. Neuroscience 211:51-76 DOI 10.1016/j.neuroscience.2011.10.057.
9. Bury A, Pienaar IS. 2013. Behavioral testing regimens in genetic-based animal models of Parkinson's disease: cogencies and caveats. Neuroscience and Biobehavioral Reviews 37:846-859 DOI 10.1016/j.neubiorev.2013.03.007.
10. Connolly BS, Lang AE. 2014. Pharmacological treatment of Parkinson disease: a review. Journal of the American Medical Association 311:1670-1683 DOI 10.1001/jama.2014.3654.
11. DeLong M, Wichmann T. 2009. Update on models of basal ganglia function and dysfunction. Parkinsonism & Related Disorders 15:S237-S240 DOI 10.1016/S1353-8020(09)70822-3.
12. Dluzen D, Horstink M. 2003. Estrogen as neuroprotectant of nigrostriatal dopaminergic system: laboratory and clinical studies. Endocrine 21:67-75 DOI 10.1385/ENDO:21:1:67.
13. Dluzen DE, McDermott JL, Liu B. 1996. Estrogen as a neuroprotectant against MPTP-induced neurotoxicity in C57/BI6 mice. Neurotoxicology and Teratology 18:603-606 DOI 10.1016/0892-0362(96)00086-4.
14. Fernagut PO, Diguet E, Labattu B, Tison F. 2002. A simple method to measure stride length as an index of nigrostriatal dysfunction in mice. Journal of Neuroscience Methods 113:123-130 DOI 10.1016/S0165-0270(01)00485-X.
15. Galna B, Murphy AT, Morris ME. 2013. Obstacle crossing in Parkinson's disease: mediolateral sway of the centre of mass during level-ground walking and obstacle crossing. Gait and Posture 38:790-794 DOI 10.1016/j.gaitpost.2013.03.024.
16. Geldenhuys WJ, Kochi A, Lin L, Sutariya V, Dluzen DE, Van der Schyf CJ, Lim MH. 2014. Methyl yellow: a potential drug scaffold for Parkinson's disease. Chembiochem 15:1591-1598 DOI 10.1002/cbic.201300770.
17. Gillies GE, Pienaar IS, Vohra S, Qamhawi Z. 2014. Sex differences in Parkinson's disease. Frontiers in Neuroendocrinology 35:370-384 DOI 10.1016/j.yfrne.2014.02.002.
18. Hanakawa T, Katsumi Y, Fukuyama H, Honda M, Hayashi T, Kimura J, Shibasaki H. 1999. Mechanisms underlying gait disturbance in Parkinson's disease: a single photon emission computed tomography study. Brain 122(Pt 7):1271-1282 DOI 10.1093/brain/122.7.1271.
19. Hartmann A. 2004. Postmortem studies in Parkinson's disease. Dialogues in Clinical Neuroscience 6:281-293.
20. Hildebrand M. 1965. Symmetrical gaits of horses. Science 150:701-708 DOI 10.1126/science.150.3697.701.
21. Jamon M, Clarac F. 1998. Early walking in the neonatal rat: a kinematic study. Behavioral Neuroscience 112:1218-1228 DOI 10.1037/0735-7044.112.5.1218.
22. Klemann CJHM, Martens GJM, Poelmans G, Visser JE. 2015. Validity of the MPTP-treated mouse as a model for Parkinson's disease. Molecular Neurobiology 1-12 Epub ahead of print Feb 13 2015 DOI 10.1007/s12035-015-9103-8.
23. Lawson RA, Yarnall AJ, Duncan GW, Khoo TK, Breen DP, Barker RA, Collerton D, Taylor JP, Burn DJ. 2014. Severity of mild cognitive impairment in early Parkinson's disease contributes to poorer quality of life. Parkinsonism & Related Disorders 20:1071-1075 DOI 10.1016/j.parkreldis.2014.07.004.
24. Lenth RV. 2014. lsmeans: least-squares means. R package version 211. Available at http://CRAN.R-project.org/package=lsmeans.
25. Matsuura K, Kabuto H, Makino H, Ogawa N. 1997. Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion. Journal of Neuroscience Methods 73:45-48 DOI 10.1016/S0165-0270(96)02211-X.
26. Mazzone P, Paoloni M, Mangone M, Santilli V, Insola A, Fini M, Scarnati E. 2014. Unilateral deep brain stimulation of the pedunculopontine tegmental nucleus in idiopathic Parkinson's disease: effects on gait initiation and performance. Gait and Posture 40:357-362 DOI 10.1016/j.gaitpost.2014.05.002.
27. McDermott JL, Kreutzberg JD, Liu B, Dluzen DE. 1994. Effects of estrogen treatment on sensorimotor task performance and brain dopamine concentrations in gonadectomized male and female CD-1 mice. Hormones and Behavior 28:16-28 DOI 10.1006/hbeh.1994.1002.
28. Meredith GE, Rademacher DJ. 2011. MPTP mouse models of Parkinson's disease: an update. Journal of Parkinson's Disease 1:19-33 DOI 10.3233/JPD-2011-11023.
29. Morin N, Jourdain VA, Di Paolo T. 2014. Modeling dyskinesia in animal models of Parkinson disease. Experimental Neurology 256:105-116 DOI 10.1016/j.expneurol.2013.01.024.
30. Obeso JA, Rodriguez-Oroz MC, Stamelou M, Bhatia KP, Burn DJ. 2014. The expanding universe of disorders of the basal ganglia. Lancet 384:523-531 DOI 10.1016/S0140-6736(13)62418-6.
31. Ozkaya N, Nordin M. 1999. Fundamentals of biomechanics: equilibrium, motion and deformation. New York: Springer.
32. Pienaar IS, Lee CH, Elson JL, McGuinness L, Gentleman SM, Kalaria RN, Dexter DT. 2015. Deep-brain stimulation associates with improved microvascular integrity in the subthalamic nucleus in Parkinson's disease. Neurobiology of Disease 74:392-405 DOI 10.1016/j.nbd.2014.12.006.
33. Pienaar IS, Lu B, Schallert T. 2012. Closing the gap between clinic and cage: sensori-motor and cognitive behavioural testing regimens in neurotoxin-induced animal models of Parkinson's disease. Neuroscience and Biobehavioral Reviews 36:2305-2324 DOI 10.1016/j.neubiorev.2012.07.009.
34. Pinheiro J, Bates D, DebRoy S, Sarkar D. 2013. nlme: linear and nonlinear mixed effects models. R package version 31-109. Available at http://CRAN.R-project.org/package=nlme.
35. R Core Team. 2013. R: a language and environment for statistical computing. 2.15.3 edition. Vienna: R Foundation for Statistical Computing.
36. Rozas G, Guerra MJ, Labandeira-García JL. 1997. An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism. Brain Research Protocols 2:75-84 DOI 10.1016/S1385-299X(97)00034-2.
37. Ruxton GD. 2006. The unequal variance t-test is an underused alternative to student's t-test and the Mann-Whitney U-test. Behavioral Ecology 17:688-690 DOI 10.1093/beheco/ark016.
38. Schmidt N, Ferger B. 2001. Neurochemical findings in the MPTP model of Parkinson's disease. Journal of Neural Transmission 108:1263-1282 DOI 10.1007/s007020100004.
39. Tieu K. 2011. A guide to neurotoxic animal models of Parkinson's disease. Cold Spring Harbor Perspectives in Medicine 1:a009316 DOI 10.1101/cshperspect.a009316.
40. Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, Nelson LM. 2003. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. American Journal of Epidemiology 157:1015-1022 DOI 10.1093/aje/kwg068.
41. Walker JA. 1998. Estimating velocities and accelerations of animal locomotion: a simulation experiment comparing numerical differentiation algorithms. Journal of Experimental Biology 201:981-995.
42. Wang XH, Lu G, Hu X, Tsang KS, Kwong WH, Wu FX, Meng HW, Jiang S, Liu SW, Ng HK, PoonWS. 2012. Quantitative assessment of gait and neurochemical correlation in a classical murine model of Parkinson's disease. BMC Neuroscience 13:142 DOI 10.1186/1471-2202-13-142.
43. Young JW. 2012. Gait selection and the ontogeny of quadrupedal walking in squirrel monkeys (Saimiri boliviensis). American Journal of Physical Anthropology 147:580-592 DOI 10.1002/ajpa.22016.